BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, December 23, 2024
Breaking News: Holiday special – 25% off BioWorld subscriptions
See today's BioWorld Science
Home
» Grant supports Vesigen’s work on genome editing therapeutic strategy for Friedreich’s ataxia
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Neurology/Psychiatric
Grant supports Vesigen’s work on genome editing therapeutic strategy for Friedreich’s ataxia
March 15, 2023
No Comments
Vesigen Therapeutics Inc. has been awarded a grant by the Friedreich’s Ataxia Research Alliance (FARA) to develop a targeted genome editing therapeutic strategy for Friedreich’s ataxia.
BioWorld Science
Neurology/psychiatric
Grant
